• 1
    Ferrara F. Unanswered questions in acute myeloid leukaemia. Lancet Oncol. 2004; 5: 443450.
  • 2
    Ravandi F,Burnett AK,Agura ED,Kantarjian HM. Progress in the treatment of acute myeloid leukemia. Cancer. 2007; 110: 19001910.
  • 3
    Ferrara F, Palmieri S, Mele G. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. Haematologica. 2004; 89: 9981008.
  • 4
    Huisman C,Meijer E,Petersen EJ,Lokhorst HM,Verdonck LF. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years. Biol Blood Marrow Transplant. 2008; 14: 181186.
  • 5
    Tsimberidou AM,Giles FJ,Estey E,O'Brien S,Keating MJ,Kantarjian HM. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol. 2006; 132: 398409.
  • 6
    Kantarjian HM,Jeha S,Gandhi V,Wess M,Faderl S. Clofarabine: past, present, and future. Leuk Lymphoma. 2007; 48: 19221930.
  • 7
    Burnett AK,Baccarani M,Johnson P, et al. A phase II study (Biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute myeloid leukemia for whom standard intensive chemotherapy is not considered suitable [abstract]. Blood. 2006; 108: 130a.
  • 8
    Faderl S,Ferrajoli A,Wierda W, et al. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer. 2008; 113: 20902096.
  • 9
    Sekeres M,Elson, P,Wang X, et al. Time from diagnosis to treatment initiation predicts survival in acute myeloid leukemia (AML) [abstract]. Blood. 2007; 110: 184a.